典型文献
Phase Ⅰ study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients
文献摘要：
Anti-CD19 chimeric antigen receptor(CAR)T cell therapy has shown impressive efficacy in treating B-cell malignancies.A single-center phase Ⅰ dose-escalation study was conducted to evaluate the safety and efficacy of T cells transduced with CBM.CD19 CAR,a second-generation anti-CD19 CAR bearing 4-1BB costimulatory molecule,for the treatment of patients with refractory diffuse large B-cell lymphoma(DLBCL).Ten heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell(C-CAR011)treatment.The overall response rate was 20％and 50％at 4 and 12 weeks after the infusion of C-CAR011,respectively,and the disease control rate was 60％at 12 weeks after infusion.Treatment-emergent adverse events occurred in all patients.The incidence of cytokine release syndrome in all grades and grade≥3 was 90％and 0,respectively,which is consistent with the safety profile of axicabtagene ciloleucel and tisagenlecleucel.Neurotoxicity or other dose-limiting toxicities was not observed in any dose cohort of C-CAR011 therapy.Antitumor efficacy was apparent across dose cohorts.Therefore,C-CAR011 is a safe and effective therapeutic option for Chinese patients with refractory DLBCL,and further large-scale clinical trials are warranted.
文献关键词：
中图分类号：
作者姓名：
Lei Fan;Li Wang;Lei Cao;Huayuan Zhu;Wei Xu;Jianyong Li
作者机构：
Department of Hematology,Pukou CLL Center Jiangsu Province Hospital,The First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China
文献出处：
引用格式：
[1]Lei Fan;Li Wang;Lei Cao;Huayuan Zhu;Wei Xu;Jianyong Li-.Phase Ⅰ study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients)[J].医学前沿,2022(02):285-294
A类：
CAR011,axicabtagene,ciloleucel,tisagenlecleucel
B类：
Phase,study,CBM,CD19,chimeric,antigen,receptor,treatment,refractory,diffuse,large,lymphoma,Chinese,patients,therapy,shown,impressive,efficacy,treating,malignancies,single,center,phase,dose,escalation,was,conducted,evaluate,safety,cells,transduced,second,generation,bearing,1BB,costimulatory,molecule,DLBCL,Ten,heavily,treated,were,given,overall,response,rate,weeks,after,infusion,respectively,disease,control,Treatment,emergent,adverse,events,occurred,incidence,cytokine,release,syndrome,grades,which,consistent,profile,Neurotoxicity,other,limiting,toxicities,not,observed,any,Antitumor,apparent,across,cohorts,Therefore,effective,therapeutic,option,further,scale,clinical,trials,warranted
AB值：
0.485655
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
